Across Europe, governments are investing billions into digital healthcare infrastructure. From interoperable health records to cross-border data-sharing initiatives, decision makers increasingly see this data as one of the region’s most valuable strategic assets.
However, despite this progress, the way medicines are evaluated often remains dependent on systems that were designed decades before the rise of artificial intelligence, wearable technologies, and real-time digital health monitoring.
Although centered on the U.S. market, a new whitepaper by Raghav Dave of Sonata Software provides a compelling preview of how healthcare evidence generation could evolve across Europe.
At the center of the report is Evidence 2.0,, which is a model that seeks to combine traditional clinical research with insights generated from real-world patient experiences.
“Technology now makes it possible to move from a drug evidence system that is episodic, siloed, and static — to one that is continuous, integrated, and dynamically updated,” the author writes.
In particular, Raghav Dave points to the fact that the healthcare sector is approaching a turning point, suggesting that tech advances now make it possible to rethink how evidence is gathered and applied.
Said the author, this evolution represents “a generational upgrade in our ability to understand what medicines do in the real world — for all patients, not just those who met trial eligibility criteria.”
Increasingly, Europe is focusing efforts to build a more connected healthcare ecosystem.
Initiatives such as the European Health Data Space are intended to make health information more accessible for research and patient care while maintaining strict privacy protections.
At the same time, healthcare systems across the continent are increasingly adopting interoperable standards that allow information to move more seamlessly between institutions. These developments could create the conditions necessary for a more sophisticated evidence infrastructure.
Historically, evidence generation has relied heavily on randomized clinical trials. While those trials remain critical for determining safety and efficacy, they often provide only a snapshot of how therapies perform under controlled conditions. The Sonata whitepaper argues that the next stage of healthcare innovation will require a broader perspective that includes data generated after treatments reach everyday clinical practice.
The report points to a convergence of technologies that is helping make that possible. “The convergence of real-world data networks, artificial intelligence, blockchain infrastructure, and connected patient devices is creating conditions that make it possible — for the first time — to build a drug evidence ecosystem that is continuous, comprehensive, transparent, and genuinely patient-centered.”
AI is expected to play a particularly significant role. Advanced analytics systems are also becoming increasingly capable of processing large volumes of healthcare data and uncovering patterns that would be difficult to detect through traditional methods.
The whitepaper also discusses the growing importance of patient-generated information. Connected devices, digital biomarkers and wearable technologies are creating streams of data that were largely unavailable to researchers only a decade ago. In to the report, it’s said that these tools have the potential to reveal “the 95% of patient experience that traditional trials never observe.”
While the white paper focuses on the U.S. healthcare system, its findings offer valuable insights for European policymakers as they shape the future of healthcare. Visit here to read the full report.
